Table 5.
Results of stereotactic body radiation therapy studies in high-risk prostate cancer
| Author | Total no. of patients (no. of HR) | Median FU (mo) | Dose (Gy) | Field Size | bRFS (%) | Toxicity |
|
|---|---|---|---|---|---|---|---|
| Grade 2, 3 GI (%) | Grade 2, 3 GU (%) | ||||||
| Kang17 | 44 (29) | 40 | 32-36/4 fx | P + SV | 90.9 | Acute: 25, 0 | Acute: 25, 0 |
| Late: 14, 0 | Late: 14, 0 | ||||||
| Bolzicco20 | 100 (17) | 36 | 35/5 fx | P + SV | 94∗ | Acute: 18, 0 | Acute: 12, 0 |
| Late: 1, 0 | Late: 3, 1 | ||||||
| Chen21 | 100 (8) | 27 | 35-36.35/5 fx | P + SV | 87.5 | Late gr ≥2; 1 | Late gr ≥2; 31 |
| King18 | 1100 (125) | 36 | 35-40/5 fx | P + SV | 81 | NR | NR |
| Lee22 | 45 (13) | 63 | 36/5 fx | P + SV | 89.7∗ | Acute: 4.4, 0 | Acute: 4.4, 0 |
| Late: 4.4, 0 | Late: 4.4, 4.4 | ||||||
| Berne-Tich23 | 142 (18) | 38 | 35-37.5/5 fx | P + SV | 83.9 | Acute: 4, 0 | Acute: 28, 2 |
| Late: 3, 0 | Late: 14, 2 | ||||||
| Davis24 | 437 (33) | 20 | 35-38/4-5 fx | P + SV | 89.8 | Acute: 1, 0 | Acute: 2, 0 |
| Late: 2, 0 | Late: 8, 0 | ||||||
| Ricco25 | 270 (32) | 50 | 35-37.5/5 fx | P + SV | 92 | Acute: NR | Acute: NR, 3.3 |
| Late: 2.7, 0 | Late: 16, 0 | ||||||
| Katz19 | 515 (38) | 72 | 35-36.25/5 fx | P + SV | 65 | Acute: < 5, 0 | Acute: < 5, 0 |
| Late: 4, 0 | Late: 9, 1.7 | ||||||
| Kotecha26 | 24 (13) | 25 | 36.25/5 fx | P + SV | 95.8∗ (boost 50 Gy) | Acute: 0, 0 | Acute: 38, 0 |
| Late: 8, 0 | Late: 4, 0 | ||||||
| Koskela27 | 218 (111) | 23 | 35-36.25/5 fx | P + SV | 92.8 | Acute: 0.4, 0 | Acute: 1.4, 0 |
| Late: NR, 0.9 | Late: NR, 1.8 | ||||||
| Murthy14 | 68 (31) | 18 | 35-37.5/5 fx | P + SV ± LN | 94∗ | Acute: 4, 0 | Acute: 12, 0 |
| Late: 4, 0 | Late: 4.5, 2.5 | ||||||
| Masunuru12 | 30 | 25 | 40/5 fx | P + SV ± LN | NR | Acute: 3.3, 0 | Acute: 46.7, 0 |
| Late: 32, 0 | Late: 52, 0 | ||||||
| Current study23 | (19) | 18 | 37.5-40/5 fx | P + SV + LN | 95.7 | Acute: 0, 0 | Acute: 36.4, 4.5 |
| Late: 9.1, 0 | Late: 27.3, 4.5 | ||||||
Abbreviations: bRFS = biochemical relapse-free survival; fx = fractions; FU = follow-up; GI = gastrointestinal; GU = genitourinary; HR = high risk; LN = pelvic lymph node; NR = not reported; P = prostate; SV = seminal vesicle.
∗
All risk subgroup.